Kavli Affiliate: Kevin Bender | Authors: Selin Schamiloglu, Elinor Lewis, Anne C Hergarden, Kevin Bender and Jennifer L Whistler | Summary: ABSTRACT Second generation antipsychotics (SGAs) are front-line treatments for serious mental illness. Often, individual patients benefit only from some SGAs and not others. The mechanisms underlying this unpredictability in treatment efficacy remain unclear. All […]
Continue.. Arrestin-3 agonism at D3 dopamine receptors defines a subclass of second generation antipsychotics that promotes drug tolerance